Video summary

🦠 India's National Leprosy Eradication Programme (NLEP) 🤝 | MDT, PEP & Nikusth 2.0 | Public Health 📚

Main summary

Key takeaways

Educational

Main ideas, concepts, and lessons

1) Progress toward leprosy eradication in India (key trends)

  • Large decline in disease prevalence
    • 1981: 57.2 leprosy cases per 10,000 population
    • 2025: 0.57 per 10,000 population
  • Disability burden reduced
    • Grade 2 disability: 4.48 per million (2014) → 1.31 per million (2025)
  • Fewer children among newly detected cases
    • 9.04% → 4.68%
  • Improved case detection outcomes
    • Annual new case detection rate: 9.73 per 1 lakh → 7 per 1 lakh

2) Evolution of the program across decades (phases)

  • Control phase (1948–1982)
    • 1948: Hind Kusht Nivaran Sangh established
    • 1955: National Leprosy Control Program launched using dapsone monotherapy
  • Eradication phase (1983 onward)
    • 1983: program upgraded to National Leprosy Eradication Program (NLEP)
    • Multi-drug therapy (MDT) introduced globally
    • 1993: World Bank support extended for MDT
    • 2005: national-level elimination achieved and program integrated into National Rural Health Mission
  • Interruption / “final mile” phase (2016–2027)
    • Reporting/software and community strategies introduced:
      • Nikust reporting software
      • Sparsh awareness campaign
      • Post-exposure prophylaxis (PEP)
    • 2023: National Strategic Plan 2023–2027 launched + Nikust 2.0
    • 2025:
      • Leprosy declared notifiable disease
      • uniform 3-drug MDT implemented

3) “Zero Framework” vision, mission, and objectives

  • Vision: a leprosy-free India
  • Mission: quality, free-of-cost, easily accessible leprosy services through an integrated healthcare system, including post-cure disability care
  • Core objectives (examples explicitly stated)
    • Reduce prevalence to < 1 per 10,000 at subnational and district levels
    • Reduce Grade 2 disability:
      • < 1% among new cases nationally
      • < 1 case per million nationally
    • Achieve zero disabilities among new child cases
    • Ensure zero stigma and discrimination

4) Program philosophy and supporting components

  • Three pillars:
    • Zero transmission
    • Zero disability
    • Zero discrimination
  • Six key components:
    1. Case detection and management (early identification to break transmission)
    2. Disability prevention and medical rehabilitation
    3. Information, education, behavior change communication
    4. Human resources and capacity building
    5. Program management and supervision
    6. Stigma reduction (restore dignity)

5) How the program is organized (policy to patient)

  • National level
    • Directorate General of Health Services + Central Leprosy Division
    • Roles: policy, central funding, national digital surveillance via Nikust 2.0
  • State level
    • State leprosy officer
    • Roles: strategy implementation and resource allocation
  • District level
    • District leprosy officer + district leprosy nucleus
    • Roles: supervision, execution of disability prevention/rehabilitation, referral networks
  • Grassroots
    • Primary Health Centers and ASHA workers
    • Roles: surveillance, direct patient contact, contact tracing, early detection

6) Multi-pronged strategy (what they do)

A) Active case detection

  • Leprosy case detection campaigns
    • 14-day intensive door-to-door surveys in high endemic districts
  • Focused leprosy campaigns
    • Targeted approach for low endemic and hard-to-reach areas

B) Transmission interruption via PEP (post-exposure prophylaxis)

  • PEP method stated
    • Give a single dose of rifampicin to eligible healthy contacts of an index case
    • Purpose: break the transmission chain immediately

C) Integrated screening across age groups

  • Children (0–18 years): screened under Rashtriya Bal Swasthya Karyakram
  • Adolescents (13–19 years): screened under Rashtriya Kishor Swasthya Karyakram
  • Adults (>30 years): screened under Ayushman Bharat

D) Information and stigma eradication

  • SPARSH Leprosy Awareness Campaigns
    • Conduct annual Gram Sabha pledges to end discrimination
  • Sapna mascot (schoolgirls representation)
    • Helps dispel myths and normalize reporting

7) Active detection cycle (explicit workflow in three connected functions)

  • Targeted surveillance
    • 14-day door-to-door campaigns in high endemic districts
    • Focused surveys in low endemic areas when triggered by:
      • Grade 2 disability or child case
    • Ongoing ASHA-based surveillance to identify suspects early
  • Immediate prevention
    • Contact tracing that retrospectively maps up to 5 years of newly detected cases
    • Provide PEP to eligible healthy contacts to cut transmission
  • Intensive monitoring
    • Special frameworks for 121 districts with prevalence rate above 1
    • District award guidelines to incentivize:
      • rapid elimination
      • treatment completion
  • Cycle goal
    • Achieve prevalence < 1 per 10,000 universally

8) Disability prevention and rehabilitation: patient journey cycle (4 stages)

  1. Primary prevention and self-care
    • Specialized dressing materials
    • supportive medicines
    • ulcer kits
    • training for self-care to protect insensitive hands/feet from injury
  2. Physical support and appliances
    • microcellular rubber footwear
    • splints and crutches
    • aim: prevent progressive deformity
  3. Surgical correction
    • reconstructive surgeries free of cost
    • across 83 centers:
      • 42 government centers
      • 41 NGO centers
      • plus central leprosy institutes
  4. Socio-economic welfare
    • Direct welfare allowance: â‚ą12,000
    • paid to each patient undergoing reconstructive surgery
    • purpose: compensate loss of wages and remove financial barriers

9) Modernization and advanced initiatives

  • Digital surveillance (NLEP 2.0, launched 2023)
    • web-based ICT portal for:
      • real-time patient recording
      • epidemiological tracking
      • vital drug stock management
  • Biological security
    • national antimicrobial resistance surveillance network
    • sentinel sites including:
      • Central Leprosy Teaching and Research Institute
      • JALMA Institute
    • monitors resistance of Mycobacterium leprae to:
      • rifampicin, dapsone, clofazimine
  • Holistic health
    • mental health services integrated for patients and families
    • addressing psychological toll of diagnosis and stigma
  • Demographic targeting
    • tagging systems in Nikust 2.0
    • monitors particularly vulnerable tribal groups across 17 states
    • under Pradhan Mantri Janjati Adivasi Nyaya Maha Abhiyan
  • Clinical shift: revised treatment protocol (from April 1, 2025)
    • Universal 3-drug MDT for both:
      • paucibacillary and multibacillary cases
    • drugs: rifampicin + dapsone + clofazimine
    • durations:
      • Paucibacillary: 6 months
      • Multibacillary: 12 months
    • dosing:
      • varies by age group (adults, children 10–14, and children <10 or <40 kg) with adjustments

10) Strategic plan outlook to 2027: “interruption of transmission”

  • Overarching goal by 2027
    • interruption of transmission defined as:
      • zero occurrence of new child cases for five consecutive years
  • Five pillars for 2023–2027
    1. Leadership, coordination, partnerships; intersectoral accountability
    2. Accelerated case detection via proactive campaigns and contact tracing
    3. Comprehensive quality services (universal access to free MDT and disability prevention/rehabilitation)
    4. Prevention of disease and discrimination:
      • scale up PEP
      • behavior change
    5. Robust surveillance and information systems using digital platforms

11) Reported milestones (2015–2025 highlights)

  • Annual new case detection: 9.73 → 7 per 1 lakh
  • Total annual cases: ~1 lakh → ~80,000
  • Grade 2 disability among new cases: 4.48 → 1.31 per million
  • Child cases: 9.04% → 4.68%
  • PEP coverage (eligible contacts): 71% (2019) → 92% (2025)
  • Districts with prevalence < 1 per 10,000: 542 → 638

12) SWOT-style assessment

  • Strengths
    • uninterrupted free MDT supply
    • strong political commitment and decentralization via National Health Mission
    • proactive case detection mechanisms
  • Weaknesses
    • shortages of designated leprosy medical officers and expert surgeons
    • logistical delays in disability prevention/rehabilitation (e.g., procurement of footwear)
    • reliance on paper-based reporting in remote areas despite Nikust 2.0
  • Opportunities
    • deeper integration of ASHA workers and persons affected by leprosy in advocacy
    • cross-program screening convergence with:
      • Rashtriya Bal Swasthya Karyakram
      • Rashtriya Kishor Swasthya Karyakram
      • Ayushman Bharat
    • strong global technical/financial backing (WHO, International Federation of Anti-Leprosy Associations)
  • Threats
    • persistent social stigma causing underreporting
    • resource reallocation during local emergencies
    • residual backlog from COVID-19 disruptions

13) Key takeaway

Leprosy is positioned as a notifiable disease with a data-driven mandate to reach zero transmission by 2027, using:

  • decentralized delivery embedded in National Health Mission
  • universal 3-drug MDT
  • expanded PEP
  • financially supported rehabilitation
  • digital surveillance (Nikust 2.0)
  • community dignity efforts (Sparsh campaign, Sapna mascot)

Speakers / sources featured (mentioned in the subtitles)

  • Directorate General of Health Services (DGHS)
  • Central Leprosy Division
  • World Bank
  • National Rural Health Mission
  • National Health Mission
  • Nikust 2.0 (software/program)
  • Sparsh Leprosy Awareness Campaign
  • ASHA workers
  • Primary Health Centers
  • Hind Kusht Nivaran Sangh
  • Rashtriya Bal Swasthya Karyakram
  • Rashtriya Kishor Swasthya Karyakram
  • Ayushman Bharat
  • Pradhan Mantri Janjati Adivasi Nyaya Maha Abhiyan
  • WHO (World Health Organization)
  • International Federation of Anti-Leprosy Associations (ILEP)

Institutions specifically named for antimicrobial resistance surveillance

  • Central Leprosy Teaching and Research Institute
  • JALMA Institute
  • Monitoring target: Mycobacterium leprae

Original video